Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


C3 glomerulonephritis (C3GN) is a disorder of excess alternative complement activation leading to glomerular injury. Following kidney transplantation, C3GN has a high recurrence rate, and the overall prognosis is poor without treatment. However, treatment efficacy is highly variable. Eculizumab, a humanized monoclonal antibody that targets complement C5 to inhibit terminal complement activity, has emerged as a potential treatment option for C3G, although data regarding its clinical utility remains limited. In this report, we describe the successful use of eculizumab to treat a patient with recurrent post-transplant C3GN caused by a C3 gene gain-of-function mutation, and also review the published literature regarding the use of eculizumab for the treatment of recurrent C3 glomerulopathy.

Original languageEnglish (US)
Pages (from-to)51-56
Number of pages6
JournalClinical nephrology
Issue number1
StatePublished - Jan 2020


  • C3 glomerulonephritis
  • C3 glomerulopathy
  • complement
  • eculizumab
  • kidney transplantation

ASJC Scopus subject areas

  • Nephrology


Dive into the research topics of 'Eculizumab in post-transplant C3 glomerulonephritis caused by a C3 mutation'. Together they form a unique fingerprint.

Cite this